Smoking Addiction-Pipeline Review, H1 2016

Smoking Addiction-Pipeline Review, H1 2016

  • Products Id :- GMDHC8176IDB
  • |
  • Pages: 107
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Smoking Addiction-Pipeline Review, H1 2016


Global Markets Direct's, 'Smoking Addiction-Pipeline Review, H1 2016', provides an overview of the Smoking Addiction pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Smoking Addiction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Smoking Addiction and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.


The report provides a snapshot of the global therapeutic landscape of Smoking Addiction

The report reviews pipeline therapeutics for Smoking Addiction by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Smoking Addiction therapeutics and enlists all their major and minor projects

The report assesses Smoking Addiction therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Smoking Addiction

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Smoking Addiction

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Smoking Addiction pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Smoking Addiction Overview 9

Therapeutics Development 10

Pipeline Products for Smoking Addiction-Overview 10

Pipeline Products for Smoking Addiction-Comparative Analysis 11

Smoking Addiction-Therapeutics under Development by Companies 12

Smoking Addiction-Therapeutics under Investigation by Universities/Institutes 14

Smoking Addiction-Pipeline Products Glance 15

Clinical Stage Products 15

Early Stage Products 16

Unknown Stage Products 17

Smoking Addiction-Products under Development by Companies 18

Smoking Addiction-Products under Investigation by Universities/Institutes 19

Smoking Addiction-Companies Involved in Therapeutics Development 20

Aradigm Corporation 20

Arena Pharmaceuticals, Inc. 21

Astraea Therapeutics, LLC 22

Bioprojet SCR 23

Cerecor Inc. 24

CoMentis, Inc. 25

Embera NeuroTherapeutics, Inc. 26

Euthymics Bioscience, Inc. 27

Invion Limited 28

Johnson & Johnson 29

Marinus Pharmaceuticals, Inc. 30

NAL Pharmaceuticals Ltd. 31

Pfizer Inc. 32

Selecta Biosciences, Inc. 33

Zynerba Pharmaceuticals, Inc. 34

Smoking Addiction-Therapeutics Assessment 35

Assessment by Monotherapy Products 35

Assessment by Combination Products 36

Assessment by Target 37

Assessment by Mechanism of Action 39

Assessment by Route of Administration 41

Assessment by Molecule Type 43

Drug Profiles 45

(metyrapone + oxazepam)-Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

amitifadine-Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

Anatabine-Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

AT-1001-Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

BP-1.4979-Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

CERC-501-Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

ganaxolone-Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

GTS-21-Drug Profile 61

Product Description 61

Mechanism Of Action 61

R&D Progress 61

JNJ-39393406-Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

lorcaserin hydrochloride-Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

nadolol-Drug Profile 74

Product Description 74

Mechanism Of Action 74

R&D Progress 74

NFL-101-Drug Profile 78

Product Description 78

Mechanism Of Action 78

R&D Progress 78

NIC7-DT-Drug Profile 79

Product Description 79

Mechanism Of Action 79

R&D Progress 79

nicotine bitartrate-Drug Profile 80

Product Description 80

Mechanism Of Action 80

R&D Progress 80

nicotine bitartrate-Drug Profile 81

Product Description 81

Mechanism Of Action 81

R&D Progress 81

Nicotine Vaccine-Drug Profile 82

Product Description 82

Mechanism Of Action 82

R&D Progress 82

PF-05402536-Drug Profile 83

Product Description 83

Mechanism Of Action 83

R&D Progress 83

PF-06413367-Drug Profile 84

Product Description 84

Mechanism Of Action 84

R&D Progress 84

SEL-070-Drug Profile 85

Product Description 85

Mechanism Of Action 85

R&D Progress 85

Small Molecule for Smoking Cessation and Appetite Suppression-Drug Profile 86

Product Description 86

Mechanism Of Action 86

R&D Progress 86

Small Molecule to Agonize Alpha 4Beta 2 and Alpha 6Beta 2 Neuronal Nicotinic Receptor for Smoking Cessation-Drug Profile 87

Product Description 87

Mechanism Of Action 87

R&D Progress 87

Small Molecules to Antagonize CHRNA3 and CHRNB4 for Smoking Cessation-Drug Profile 88

Product Description 88

Mechanism Of Action 88

R&D Progress 88

Small Molecules to Antagonize CHRNB2 and CHRNA4 for Smoking Cessation-Drug Profile 89

Product Description 89

Mechanism Of Action 89

R&D Progress 89

URB-694-Drug Profile 90

Product Description 90

Mechanism Of Action 90

R&D Progress 90

Smoking Addiction-Dormant Projects 91

Smoking Addiction-Discontinued Products 93

Smoking Addiction-Product Development Milestones 94

Featured News & Press Releases 94

Apr 11, 2016: Cerecor Announces USD 1.0 Million Research & Development Grant from the National Institute on Drug Abuse (NIDA) at the National Institutes of Health 94

Feb 02, 2016: Cerecor Announces Initiation of Phase 2 Clinical Trial With CERC-501 for Smoking Cessation 94

Nov 17, 2015: Invion Phase 2 Smoking Cessation Data: Results of Ongoing Analysis 95

Oct 05, 2015: Invion Successfully Completes Phase 2 Study of INV102 to Aid Smoking Cessation 95

Jun 29, 2015: Invion completes dosing in key phase II clinical trial of oral INV102 in smoking cessation 97

Feb 02, 2015: Invion completes enrolment in its phase II trial of oral INV102 (nadolol) in smoking cessation 98

Jan 19, 2015: Invion Announces Positive Interim Data from Its Phase II Clinical Trial of Oral Inv102 (nadolol) in Smoking Cessation 99

Nov 04, 2014: Lorcaserin Meets Primary Endpoint And Confirms Proof-Of-Concept As Potential Aid For Smoking Cessation In Investigational Phase II Clinical Study 100

Nov 03, 2014: Eisai and Arena Pharmaceuticals Report Results of an Investigational Phase 2 Trial of Lorcaserin HCl as an Aid for Smoking Cessation 100

Jul 01, 2014: Embera NeuroTherapeutics to Receive Grant for Clinical Trial Through New Crowd Funding Platform 101

May 09, 2014: Arena Pharmaceuticals Reports that Eisai Plans to Further Increase its Sales Force for BELVIQ (lorcaserin HCl) CIV by 50% 102

Jan 29, 2014: FDA clears path for Smoking Cessation clinical trial of INV102 (nadolol) 102

Nov 11, 2013: Change to FDA reviewing division for smoking cessation clinical trial 103


Dec 19, 2012: Invion Provides Update On INV102 Phase II Clinical Programs 104

Appendix 106

Methodology 106

Coverage 106

Secondary Research 106

Primary Research 106

Expert Panel Validation 106

Contact Us 106

Disclaimer 107

List of Figures

Number of Products under Development for Smoking Addiction, H1 2016 10

Number of Products under Development for Smoking Addiction-Comparative Analysis, H1 2016 11

Number of Products under Development by Companies, H1 2016 12

Number of Products under Investigation by Universities/Institutes, H1 2016 14

Comparative Analysis by Clinical Stage Development, H1 2016 15

Comparative Analysis by Early Stage Products, H1 2016 16

Assessment by Monotherapy Products, H1 2016 35

Number of Products by Top 10 Targets, H1 2016 37

Number of Products by Stage and Top 10 Targets, H1 2016 37

Number of Products by Top 10 Mechanism of Actions, H1 2016 39

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 39

Number of Products by Routes of Administration, H1 2016 41

Number of Products by Stage and Routes of Administration, H1 2016 41

Number of Products by Molecule Types, H1 2016 43

Number of Products by Stage and Molecule Types, H1 2016 43

List of Tables

Number of Products under Development for Smoking Addiction, H1 2016 10

Number of Products under Development for Smoking Addiction-Comparative Analysis, H1 2016 11

Number of Products under Development by Companies, H1 2016 13

Number of Products under Investigation by Universities/Institutes, H1 2016 14

Comparative Analysis by Clinical Stage Development, H1 2016 15

Comparative Analysis by Early Stage Development, H1 2016 16

Comparative Analysis by Unknown Stage Development, H1 2016 17

Products under Development by Companies, H1 2016 18

Products under Investigation by Universities/Institutes, H1 2016 19

Smoking Addiction-Pipeline by Aradigm Corporation, H1 2016 20

Smoking Addiction-Pipeline by Arena Pharmaceuticals, Inc., H1 2016 21

Smoking Addiction-Pipeline by Astraea Therapeutics, LLC, H1 2016 22

Smoking Addiction-Pipeline by Bioprojet SCR, H1 2016 23

Smoking Addiction-Pipeline by Cerecor Inc., H1 2016 24

Smoking Addiction-Pipeline by CoMentis, Inc., H1 2016 25

Smoking Addiction-Pipeline by Embera NeuroTherapeutics, Inc., H1 2016 26

Smoking Addiction-Pipeline by Euthymics Bioscience, Inc., H1 2016 27

Smoking Addiction-Pipeline by Invion Limited, H1 2016 28

Smoking Addiction-Pipeline by Johnson & Johnson, H1 2016 29

Smoking Addiction-Pipeline by Marinus Pharmaceuticals, Inc., H1 2016 30

Smoking Addiction-Pipeline by NAL Pharmaceuticals Ltd., H1 2016 31

Smoking Addiction-Pipeline by Pfizer Inc., H1 2016 32

Smoking Addiction-Pipeline by Selecta Biosciences, Inc., H1 2016 33

Smoking Addiction-Pipeline by Zynerba Pharmaceuticals, Inc., H1 2016 34

Assessment by Monotherapy Products, H1 2016 35

Assessment by Combination Products, H1 2016 36

Number of Products by Stage and Target, H1 2016 38

Number of Products by Stage and Mechanism of Action, H1 2016 40

Number of Products by Stage and Route of Administration, H1 2016 42

Number of Products by Stage and Molecule Type, H1 2016 44

Smoking Addiction-Dormant Projects, H1 2016 91

Smoking Addiction-Dormant Projects (Contd..1), H1 2016 92

Smoking Addiction-Discontinued Products, H1 2016 93

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Aradigm Corporation

Arena Pharmaceuticals, Inc.

Astraea Therapeutics, LLC

Bioprojet SCR

Cerecor Inc.

CoMentis, Inc.

Embera NeuroTherapeutics, Inc.

Euthymics Bioscience, Inc.

Invion Limited

Johnson & Johnson

Marinus Pharmaceuticals, Inc.

NAL Pharmaceuticals Ltd.

Pfizer Inc.

Selecta Biosciences, Inc.

Zynerba Pharmaceuticals, Inc.

Smoking Addiction Therapeutic Products under Development, Key Players in Smoking Addiction Therapeutics, Smoking Addiction Pipeline Overview, Smoking Addiction Pipeline, Smoking Addiction Pipeline Assessment

select a license
Single User License
USD 2000 INR 147300
Site License
USD 4000 INR 294600
Corporate User License
USD 6000 INR 441900



An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]